Results 1 to 10 of about 1,902 (217)
JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis [PDF]
Journal of Immunotherapy and Precision Oncology, 2021 Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by uncontrolled blood counts, constitutional symptoms, extramedullary hematopoiesis, and an increased risk of developing acute myeloid leukemia.
Andrew T. Kuykendall, Rami S. Komrokji
doaj +4 more sources
JAK Inhibitor and Crohn’s Disease
BiomedicinesCrohn’s disease is a chronic inflammatory granulomatous disease of the gastrointestinal tract. The global incidence and prevalence of Crohn’s disease have significantly increased, largely due to genetic susceptibility, environmental changes, and ...
Mengyan Xu +3 more
doaj +3 more sources
Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors
Allergology International, 2022 Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin lesions. The knowledge on the pathogenesis of AD is driving the development of new drugs. From the research results, it has been revealed that Th2 cell-mediated immunity,
Chisa Nakashima +2 more
doaj +1 more source
Indian Journal of Dermatology, Venereology and Leprology, 2023 The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a key regulatory signaling system for cellular proliferation, differentiation, and apoptosis. In addition, JAK signaling pathway plays critical roles in orchestrating immune response through its interactions with the cytokine receptors and the transcriptions ...
Siba P, Raychaudhuri +1 more
openaire +2 more sources
JAK inhibitors in rheumatology
Immunological Medicine, 2023 Janus kinase inhibitors (JAKis) are a group of drugs with a different mechanism of action from biologics and are most rapidly uptaken in the rheumatology field. JAK is a protein kinase activated in the cytoplasm by multiple cytokines and hormones involved in inflammatory pathology. The expression of JAK has been observed in various diseases, indicating
Kunihiro Yamaoka, Kenji Oku
openaire +3 more sources
Journal of Allergy and Clinical Immunology, 2021 Asthma is an inflammatory disease of the airways characterized by intermittent episodes of wheezing, chest tightness, and cough. Many of the inflammatory pathways implicated in asthma involve cytokines and growth factors that activate Janus kinases (JAKs).
Steve N, Georas +3 more
openaire +3 more sources
The safety of JAK-1 inhibitors [PDF]
Rheumatology, 2021 Abstract As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; monitoring for laboratory ...
Benjamin Clarke +4 more
openaire +3 more sources
Turkderm Turkish Archives of Dermatology and Venereology, 2022 Tofacitinib is an oral inhibitor of janus kinases, which is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adults; its efficacy in the treatment of psoriasis has also been demonstrated in clinical ...
Nilgün Şentürk
doaj +1 more source
Inflammation and Regeneration, 2023 Background Rheumatoid arthritis (RA) is characterized by chronic inflammation and resultant cartilage/bone destruction because of aberrantly activated osteoclasts.
Shinya Yari +8 more
doaj +1 more source
Inflammation and Regeneration, 2023 Background The types of bone damage in rheumatoid arthritis (RA) include joint erosion, periarticular osteoporosis, and systemic osteoporosis. Janus kinase (JAK) inhibitors ameliorate inflammation and joint erosion in RA, but their effect on the three ...
Masatsugu Komagamine +8 more
doaj +1 more source